Search results
Author(s):
Julius Nikorowitsch
Added:
2 years ago
EHRA 24 - We are joined onsite by Dr Julius Nikorowitsch (University Heart and Vascular Centre Hamburg (UHZ), DE) to outline the impact of age, sex, cardiovascular comorbidities, and kidney function on outcomes with oral anticoagulation therapy in patients with device-detected atrial fibrillation in a substudy of the NOAH-AFNET 6 trial (NCT02618577).The substudy consisted of 2534 patients from…
View more
Added:
3 months ago
Source:
Arrhythmia Academy
In atrial fibrillation (AF) patients post one-year drug-eluting stent (DES) implantation, non–vitamin K antagonist oral anticoagulant (NOAC) was shown to be noninferior to NOAC plus clopidogrel combination therapy.¹ Current guidelines recommend NOAC monotherapy in this patient population, but supporting evidence has been limited.²MethodologyThe ADAPT AF-DES trial was a multicenter, randomised,…
View more
Renal Impact: Rivaroxaban Versus Vitamin K Antagonists in AF
Author(s):
Phong Phan Dinh
,
Tri Huynh Quang Ho
,
Hung Manh Pham
,
et al
Added:
1 year ago
Systematic Review
Anticoagulation in Cardio-oncology
Author(s):
Sebastian Szmit
,
Maciej Krzakowski
,
Dariusz M Kowalski
,
et al
Added:
3 months ago
Review Article
Author(s):
Ton Duy Mai
,
Tri Huynh Quang Ho
,
Sy Van Hoang
,
et al
Added:
1 year ago
Author(s):
Manav Sohal
Added:
1 year ago
Anticoagulant Use in Older Adults
Author(s):
Monika Bhandari
,
Akshyaya Pradhan
,
Pravesh Vishwakarma
,
et al
Added:
1 year ago
Review Article
Systematic Scoping on DOACS in NVAF Patients
Author(s):
Shirley Siang Ning Tan
,
Wei Hong Lai
,
Lee Len Tiong
,
et al
Added:
10 months ago
Review Article
Current Perspectives in Cardio-oncology
Author(s):
Ludovica Leo
,
Massimiliano Camilli
Added:
2 weeks ago
Editorial
Author(s):
Saibal Kar
,
Harriette Van Spall
Added:
2 months ago
ACC.26 – Late-breaker host Harriette Van Spall (McMaster University, Hamilton, CA) is joined by Saibal Kar, MD (Los Robles Regional Medical Center, US) to discuss CHAMPION‑AF (NCT04394546), a global randomized trial comparing the WATCHMAN FLX left atrial appendage closure device with non–vitamin K oral anticoagulants in patients with non‑valvular atrial fibrillation at elevated stroke risk…
View more